RNAZ TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. (RNAZ) Institutional Ownership
What the institutions did with RNAZ last quarter, from their 13F filings. Counting managers rather than shares is the point: a single index fund adding to a position tells you far less than four hundred separate managers all deciding to. Positions as reported for the quarter ended June 30, 2026.
Every manager below opens. Subscribers can see any firm's whole portfolio — every position, its weight, and what they bought, trimmed and exited last quarter.
Sign in or subscribeLargest holders
| Manager | Shares | % of reported |
|---|---|---|
| Yorkville Advisors Global, LP | 19.6K | 58.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.5K | 19.5% |
| VANGUARD FIDUCIARY TRUST CO | 3.0K | 8.9% |
| UBS Group AG | 2.9K | 8.6% |
| FMR LLC | 706 | 2.1% |
| Tower Research Capital LLC (TRC) | 677 | 2.0% |
| WELLS FARGO & COMPANY/MN | 55 | 0.2% |
| SBI Securities Co., Ltd. | 12 | 0.0% |
Largest changes
| Manager | Action | Previous | Current | Change |
|---|---|---|---|---|
| Yorkville Advisors Global, LP | New | 0 | 19.6K | +19.6K |
| GEODE CAPITAL MANAGEMENT, LLC | Sold Out | 12.7K | 0 | -12.7K |
| UBS Group AG | Reduced | 8.3K | 2.9K | -5.4K |
| FMR LLC | New | 0 | 706 | +706 |
| Tower Research Capital LLC (TRC) | Increased | 228 | 677 | +449 |
| ROYAL BANK OF CANADA | Sold Out | 8 | 0 | -8 |
13F filings are due 45 days after quarter end and cover long positions in U.S.-listed equities only, so this is a lagged and partial picture: shorts, bonds and foreign listings never appear. Options positions are excluded here rather than folded into the share counts. Political ownership is coming.